- About Us
- Nano-Social Network
- Nano Consulting
- My Account
Wall Street Savant, LLC ( http://www.wallstreetsavant.com ) today announced initiation of Profile Coverage on Eugene Science, Inc. on its website.
Eugene Science, Inc. is a global Biotechnology company tackling ailments such as heart disease, obesity and diabetes through innovation in the Nutraceutical field. Its first commercial heart disease product, CZ™ is a patented, Nanoscience-based, water-soluble functional food ingredient containing natural plant sterols that help maintain healthy cholesterol levels by inhibiting its absorption.
Eugene Science is advancing the era of Pharmacogenomics, a pioneering field of Biotechnology, which is the predictive and personalized treatment of adult disease through individualized manipulation of foods, medicines, food and genes. These advances are made possible by the combination of Eugene Science's database on adult diseases combined with the Company's applied Bioinformatics technology.
To view Eugene Science's Profile please visit http://www.wallstreetsavant.com .
WallStreetSavant.com is a leading online financial portal where investors can discover an array of financial tools to help build their investment IQ. WallStreetSavant.com also provides comprehensive profiles on undiscovered and under-followed micro and small-cap companies as well as well researched opinions on stocks for active traders. The comprehensive profiles are featured on WallStreetSavant.com and members are kept abreast on all new developments through regular email updates.
To join their free email list please click here:
To feature your publicly traded company on WallStreetSavant.com, please contact them at 1-800-281-6469 or via email at
Forward-Looking Statements: With the exception of historical information, this news release and accompanying information may include forward-looking statements that involve a number of risks and uncertainties. Actual results could differ materially from those anticipated as a result of various risks. There are numerous factors that could contribute to such differences; therefore, such projected events and anticipated results are not warranties or guarantees that such events will occur or that the Company will achieve such results. For more information about this corporation and risks involved in the investment of their publicly traded shares, please see the Company's web site, and/or documents filed with the SEC. Disclosure: Wall Street Savant LLC expects to be compensated fifty thousand shares of EUSI by a non-controlling third party for profile coverage. Wall Street Savant LLC is not a registered investment advisers or broker/dealer. Wall Street Savant LLC makes no recommendation that the purchase of securities of companies profiled in its web site is suitable or advisable for any person or that an investment in such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk.
For more information, please click here
Wall Street Savant, LLC
Copyright © WallStreetSavant.comIf you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
Harris & Harris Group Issues Its Financial Statements as of December 31, 2016, Posts Its Annual Shareholder Letter, And Will Host a Conference Call for Shareholders on Friday, March 17, 2017 March 15th, 2017
Arrowhead Provides Response to New Minority Shareholder Announcement January 7th, 2017
NIST physicists show ion pairs perform enhanced 'spooky action' March 30th, 2017